Novo Nordisk Pursues Injunction to Block Eli Lilly's (LLY) Advertisements
I'm LongbridgeAI, I can summarize articles.Novo Nordisk is seeking a U.S. court injunction to block Eli Lilly's advertisements for its weight-loss drugs, alleging false advertising and unfair competition. Novo claims Lilly's marketing misleads consumers by comparing outdated high-dose data against lower doses of Novo's medications. Eli Lilly denies wrongdoing and intends to defend itself in court. This legal battle highlights the intense rivalry between the two pharmaceutical giants competing for dominance in the rapidly growing obesity treatment market.
Novo Nordisk (NVO) has escalated its feud with rival drug maker Eli Lilly (LLY) by seeking a court injunction to immediately block Lilly's weight-loss drug advertisements.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Novo Nordisk is suing Eli Lilly, arguing that consumers are being misled by advertisements that compare the companies' obesity medications. Now, Novo Nordisk is seeking a U.S. court injunction to halt Eli Lilly's ads after the company refused to voluntarily remove the disputed marketing materials.
Eli Lilly has denied any wrongdoing, saying it stands by its advertising and will defend itself in court. Novo Nordisk and Eli Lilly are battling for dominance of the weight-loss drug market that analysts forecast could be worth more than $100 billion by 2030 in the U.S. alone.
Outdated Studies?
Novo Nordisk claims that Eli Lilly's advertisements are based on "outdated studies" and provide false impressions that the U.S. pharmaceutical company's drugs are vastly superior. "Novo Nordisk is seeking a court order on an expedited basis to ensure people can access the accurate, complete picture of the treatments available to them," said the European pharma giant.
Novo Nordisk's lawsuit alleges that Eli Lilly has violated false advertising and unfair competition laws in the U.S. through its campaigns to promote its various weight-loss and diabetes treatments. Novo Nordisk claims that Eli Lilly compared the highest approved doses of its drugs against lower doses of Novo's medications and omitted newer, higher-dose versions that it says deliver greater weight loss.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 22 Wall Street analysts. That rating is based on 20 Buy and two Hold recommendations issued in the last three months. The average LLY price target of $1,294.06 implies 17% upside from current levels.